FDA put seven grey-market longevity peptides through formal review — a Pharmacy Compounding Advisory Committee sitting on 23–24 July 2026 (held at signal)

Why it matters (spine). BPC-157, TB-500, MOTS-c, Semax and Epitalon are the working inventory of the longevity-clinic and biohacker economy — sold, injected, and discussed at enormous volume with essentially no regulatory adjudication behind them. Section 503A of the Federal Food, Drug, and Cosmetic Act is the mechanism that decides whether a pharmacist may legally compound a drug from a bulk substance, and the Bulks List is the ledger of what has passed. FDA convening its compounding committee on seven of these substances at once, with a published scientific briefing document for each, is the first time this market has been made to answer a regulator's question in public. Money angle: the difference between "grey-market peptide" and "legally compoundable bulk substance" is the difference between a cash-only clinic and an insurable, scalable, marketable therapeutic line — the list is the switch. Metacrisis lever: the substances people are already injecting for healthspan are being assessed for actual safety at actual exposures, which is precisely the non-toxic, human-health spine the platform exists to serve; whichever way the votes went, an evidence record now exists where there was none.

What would prove it wrong (falsifier). If the FDA advisory-committee calendar shows no PCAC meeting on 23–24 July 2026, or shows a different substance list, or if the seven briefing documents are absent from the event-materials table, this card fails. The significance claim fails if the outcome turns out to be procedurally inert — advisory committees make non-binding recommendations, and even a favourable vote requires subsequent FDA rulemaking before anything may lawfully be compounded. Nothing on this list is legal to compound today by virtue of this meeting.

Why this is a signal and not verified (the honest limit). The in-window event is the meeting itself, on 23–24 July 2026. The primary I actually read — FDA's own event page — is stamped "Content current as of: 06/29/2026", which is outside this sweep's window (22–28 July), and it is a notice of a scheduled meeting, not a record of what happened. I could not read any FDA transcript, minutes, or updated Bulks List confirming that the committee convened or how it voted. Vote tallies are circulating (reported as narrow splits in favour of several substances and a rejection of emideltide/DSIP), but every source for them is a commercially interested peptide vendor or a law blog — leads, not primaries — so no tallies appear on this card. Per the standing rule that a primary older than the window is demoted rather than stretched, this sits at signal. Promotion path: the FDA meeting transcript/minutes, the webcast archive, or an updated 503A Bulks List entry; any one of those, dated, promotes this to verified with the outcome attached.

Provenance (what I actually read). Fetched the FDA event page in session on 28 July 2026. Verbatim from the agenda: "On July 23, 2026, the Committee will discuss the following bulk drug substances being considered for inclusion on the 503A Bulks List: BPC-157-related bulk drug substances (BPC-157 (free base)/ BPC-157 acetate), KPV-related bulk drug substances (KPV (free base)/ KPV acetate), TB-500-related bulk drug substances (TB-500 (free base)/ TB-500 acetate), and MOTs-C-related bulk drug substances (MOTs-C (free base)/ MOTs-C acetate)." Day two covers "Emideltide (also referred to as delta sleeping inducing peptide (DSIP))-related bulk drug substances ... Semax-related bulk drug substances ... and Epitalon-related bulk drug substances." The uses FDA reviewed are tabulated on the page: BPC-157 for ulcerative colitis; KPV for wound healing and inflammatory conditions; TB-500 for wound healing; MOTS-c for obesity and osteoporosis; emideltide for opioid withdrawal, chronic insomnia and narcolepsy; Semax for cerebral ischemia, migraine and trigeminal neuralgia; Epitalon for insomnia. Eight FDA briefing documents are linked in the Event Materials table, one introduction plus one per substance. The page also states the constitutional limit plainly: "Advisory committees make non-binding recommendations to the FDA, which generally follows the recommendations but is not legally bound to do so." Meeting location: FDA White Oak Campus, Building 31, the Great Room. Public docket FDA-2025-N-6895, closed 22 July 2026; submission instructions on the same page reference Docket No. FDA-2026-N-2979 for the notice of meeting.

Correction discipline. The substance is emideltide (delta sleep-inducing peptide, DSIP) — use FDA's spelling. FDA renders the mitochondrial peptide as "MOTs-C" on this page; the literature standard is MOTS-c. Note also what these were reviewed for: FDA evaluated BPC-157 against ulcerative colitis and MOTS-c against obesity and osteoporosis — not against the general "healing" and "longevity" claims under which they are actually marketed. Do not let the marketing indication be mistaken for the reviewed indication.